WOMEN'S HEALTH

HPV and Cervical Cancer Detection Methodologies

Labcorp offers the latest molecular tests and cervical cytology technologies to aid in the detection of cervical cancer.

Studies show that HPV is found in **99.7%** of all cervical carcinomas.[1]

When using Pap testing with HPV DNA, the combined sensitivity for detecting high-grade cervical disease and cancer has been reported as **more than 99%**.[2,3]

Several leading health organizations and governmental agencies have provided guidance on HPV testing together with a Pap test for **women age 30 and older.**

Labcorp offers two FDA-approved HPV screening test options.

These methods are approved (1) for Pap with HPV testing for women age 30 and older and (2) for women age 21 and older as a reflex option with an ASC-US Pap result.

Aptima® HPV mRNA Test

This test utilizes transcription-mediated amplification (TMA) technology and detects mRNA from 14 high-risk HPV types associated with cervical cancer.[4] Aptima detects HPV type 16 and HPV types 18/45 (18 is not differentiated from type 45).[4]

The cobas® HPV DNA Test

This test utilizes an amplified molecular technology known as "polymerase chain reaction" (PCR) to detect HPV type 16 and HPV type 18 individually while simultaneously detecting 12 additional oncogenic HPV types in a combined format on a single specimen.[5]

labcorp

HPV Test Method Options

The Aptima® HPV Assay High-risk group mRNA method*	The Roche HPV High-risk group cobas® method**	
ThinPrep® only		
Test No.	Test No.	Test Description
193060†	**193090**†	Cervical Cancer and *Chlamydia/Gonorrhea* Screening
193065†	**193085**†	Cervical Cancer Screening Only
193070†	**193095**†	Cervical Cancer Screening plus *Chlamydia trachomatis, Neisseria gonorrhoeae*
193075†	**193100**†	Cervical Cancer Screening plus *Chlamydia trachomatis, Neisseria gonorrhoeae,* and *Trichomonas vaginalis*
199305	**196305**	Image-guided Pap, HPV With Reflex to HPV Genotype
199310	**NA**	Image-guided Pap, Ct/Ng, HPV With Reflex to HPV Genotype
199315	**NA**	Image-guided Pap, Ct/Ng/Tv, HPV With Reflex to HPV Genotype
NA	**196210**	Image-guided Pap, HPV High-risk Group and HPV Genotype
NA	**196215**	Image-guided Pap, Ct/Ng, HPV High-risk Group and HPV Genotype
NA	**196220**	Image-guided Pap, Ct/Ng/Tv, HPV High-risk Group and HPV Genotype
199300	**196310**	Image-guided Pap With Reflex to HPV when ASC-U
199320	**196315**	Image-guided Pap, Ct/Ng, With Reflex to HPV when ASC-U
199325	**NA**	Image-guided Pap, Ct/Ng/Tv, With Reflex to HPV when ASC-U
NA	**196225**	Image-guided Pap With Reflex to HPV High-risk Group and HPV Genotype When ASC-U
NA	**196230**	Image-guided Pap, Ct/Ng, With Reflex to HPV High-risk Group and HPV Genotype When ASC-U
NA	**196235**	Image-guided Pap, Ct/Ng/Tv, With Reflex to HPV High-risk Group and HPV Genotype When ASC-U
199345	**NA**	Image-guided Pap, Liquid-based Prep With Reflex to HPV High-risk DNA Detection When ASC-U, ASC-H, LSIL, HSIL, AGUS
199355	**NA**	Image-guided Pap, Liquid-based Prep, Ct/Ng, NAA With Reflex to HPV High-risk DNA Detection When ASC-U, ASC-H, LSIL, HSIL, AGUS
199360	**NA**	Image-guided Pap, Liquid-based Prep, Ct/Ng/Tv, NAA With Reflex to HPV High-risk DNA Detection When ASC-U, ASC-H, LSIL, HSIL, AGUS
507800	**NA**	Human Papillomavirus (HPV), High-risk Group
507805	**NA**	HPV High-risk Group With Reflex to HPV Genotype
NA	**507385**	HPV High-risk Group and HPV Genotype

*The test detects the same high-risk HPV types listed above in addition to HPV type 66 for a total of 14 different HPV high-risk types. Genotype includes HPV types 16, 18/45.
**HPV types 16 and 18.
† Age-based test options based on ACOG guidelines[1,2]

The Roche HPV High-risk group cobas® method for SurePath™ only.

Test No.	Test Description	Test No.	Test Description
196100	Image-guided Pap, CtNg, cobasHPV16/18	**196115**	Image-guided Pap, CtNgTvrfxcobasHPV16/18ASCU
196110	Image-guided Pap, CtNg,rfxcobasHPV16/18ASCU	**196105**	Image-guided Pap, CtNgTv, cobasHPV16/18
196335	Image-guided Pap, rfxcobasHPV16/18ASCU	**196190**	Image-guided Pap, cobasHPV16/18

NOTE: When ordering a test that includes Chlamydia/Gonococcus/ Trichomonas an Aptima® dedicated device is required.

References
1. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasivecervical cancer worldwide. J Pathol.1999;189:12-19.
2. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003; 362:1871-1876.
3. Lorincz A, Richart R. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med. 2003;127:959-968.
4. Aptima HPV Assay [package insert]. San Dieco, Calif: Gen-Probe; 2011. Rev 502170.
5. Cobas® HPV test [package insert]. Indianapolis, Ind; Roche Diagnostics; 2011.
6. American College of Obstetricians and Gynecologists. Screening for Cervical Cancer and Prevention. ACOG Practice Bulletin. No. 157, January 2016. Obstet Gynecol. 2016 Jan; 127(1): e2-e20.
7. American College of Obstetricians and Gynecologists. Primary and Preventive Care: Periodic Assessments. ACOG Committee Opinion. No. 483, April 2011. Obstet Gynecol. 2011 April; 117(4):1008-1015.

Visit the online Test Menu at **Labcorp.com**
for full test information, including specimen collection requirements.

labcorp